Prelude Capital Management, LLC Zymeworks Inc. Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$4.82 - $7.7 $33,103 - $52,883	6,868 Added 58.69%	18,570 $98,000
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $12 - $33	2 Added 0.02%	11,702 $77,000
Q4 2021 Feb 14, 2022	BUY	$15.19 - $29.33 $177,723 - $343,161	11,700 New	11,700 $192,000
Q3 2020 Nov 16, 2020	SELL	$29.21 - $46.58 $359,458 - $573,213	-12,306 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$33.67 - $40.0 $67,441 - $80,120	-2,003 Reduced 14.0%	12,306 $444,000
Q1 2020 May 15, 2020	SELL	$24.28 - $49.8 $381,026 - $781,511	-15,693 Reduced 52.31%	14,309 $508,000
Q4 2019 Feb 14, 2020	SELL	$24.84 - $45.46 $460,384 - $842,555	-18,534 Reduced 38.19%	30,002 $1.36 Million
Q3 2019 Nov 14, 2019	BUY	$22.78 - $29.08 $1.11 Million - $1.41 Million	48,536 New	48,536 $1.2 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $906M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.